Moderna burnishes its PhIII-ready Covid-19 vaccine with promising mouse data — which suggest one dose might be enough after all
Moderna and the NIH didn’t wait for animal data to begin testing its mRNA vaccine candidate in patients. But on the same day they unveiled plans for an ultra-fast Phase III in July, scientists also released mouse data that they say back up and inform the pivotal study.
In a preprint, the combined team from Anthony Fauci-led NIAID and Moderna’s infectious disease unit reported their vaccine generated “potent neutralizing activity” and appeared to protect mice from a viral infection up to 13 weeks post-injection. Perhaps more importantly, no safety signals emerged when they challenged the mice with the coronavirus.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,100+ biopharma pros reading Endpoints daily — and it's free.